Methods of Managing Traumatic Brain Injury

Abstract

This disclosure relates to methods of treating or preventing traumatic brain injury (TBI) or related conditions comprising administering an effective amount of poly [4-styrenesulfonic acid-co-maleic acid] (PSCMA) or alternative anionic polymer or a pharmaceutically acceptable salt thereof to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating chronic traumatic encephalopathy (CTE) comprising administering an effective amount of poly [4-styrenesulfonic acid-co-maleic acid] (PSCMA) or alternative anionic polymer, or a pharmaceutically acceptable salt thereof to subject in need thereof.

What is claimed is: 
     
         1 . A method of treating traumatic brain injury comprising administering an effective amount of poly [4-styrenesulfonic acid-co-maleic acid] (PSCMA) or a pharmaceutically acceptable salt thereof to a human patient in need thereof. 
     
     
         2 . The method of  claim 1 , wherein the subject experienced a concussion and was unconscious for more than one second. 
     
     
         3 . The method of  claim 1 , wherein the subject experienced a concussion and was unconscious for more than 10 seconds. 
     
     
         4 . The method of  claim 1 , wherein the subject does not have a neurodegenerative disease. 
     
     
         5 . The method of  claim 1 , wherein the subject does not have Alzheimer's disease. 
     
     
         6 . The method of  claim 1 , wherein PSCMA is administered in combination with a second therapeutic agent. 
     
     
         7 . The method of  claim 6 , wherein the second therapeutic agent is an anti-inflammatory agent. 
     
     
         8 . The method of  claim 6 , wherein the second therapeutic agent is a glucocorticoid, dexamethasone, progesterone, or methylprednisolone. 
     
     
         9 . The method of  claim 6 , wherein the second therapeutic agent is a non-steroidal anti-inflammatory drug, indomethacin, ibuprofen, carprofen, or celecoxib. 
     
     
         10 . The method of  claim 6 , wherein the second therapeutic agent is a statin, simvastatin, atorvastatin, or lovastatin. 
     
     
         11 . A method of treating chronic traumatic encephalopathy comprising administering an effective amount of poly [4-styrenesulfonic acid-co-maleic acid] (PSCMA) or a pharmaceutically acceptable salt thereof to a human patient in need thereof. 
     
     
         12 . The method of  claim 11 , wherein the subject experienced a concussion and was unconscious for more than one second. 
     
     
         13 . The method of  claim 11 , wherein the subject experienced head a concussion and was unconscious for more than 10 seconds. 
     
     
         14 . The method of  claim 11 , wherein the subject does not have a neurodegenerative disease. 
     
     
         15 . The method of  claim 11 , wherein the subject does not have Alzheimer's disease. 
     
     
         16 . The method of  claim 11 , wherein PSCMA is administered in combination with a second therapeutic agent. 
     
     
         17 . The method of  claim 16 , wherein the second therapeutic agent is an anti-inflammatory agent. 
     
     
         18 . The method of  claim 16 , wherein the second therapeutic agent is a glucocorticoid, dexamethasone, progesterone, or methylprednisolone. 
     
     
         19 . The method of  claim 16 , wherein the second therapeutic agent is a non-steroidal anti-inflammatory drug, indomethacin, ibuprofen, carprofen, or celecoxib. 
     
     
         20 . The method of  claim 16 , wherein the second therapeutic agent is a statin, simvastatin, atorvastatin, or lovastatin.